Nonpungent N-AVAM Capsaicin Analogues and Cancer Therapy
Document Type
Article
Publication Date
1-2021
Abstract
Capsaicin displays robust growth-inhibitory activity in multiple human cancers. However, the feasibility of capsaicin as a clinically relevant anticancer drug is hampered by its adverse side effects. This concern has led to extensive research focused on the isolation and synthesis of second-generation nonpungent capsaicin analogues with potent antineoplastic activity. A major class of nonpungent capsaicin-like compounds belongs to the N-acyl-vanillylamide (N-AVAM) derivatives of capsaicin (hereafter referred as N-AVAM capsaicin analogues). This perspective discusses the isolation of N-AVAM capsaicin analogues from natural sources as well as their synthesis by chemical and enzymatic methods. The perspective describes the pharmacokinetic properties and anticancer activity of N-AVAM capsaicin analogues. The signaling pathways underlying the growth-inhibitory effects of N-AVAM capsaicin analogues have also been highlighted. It is hoped that the insights obtained in this perspective will facilitate the synthesis of a second generation of N-AVAM capsaicin analogues with improved stability and growth-suppressive activity in human cancer.
Recommended Citation
Stephen D. Richbart, Jamie R. Friedman, Kathleen C. Brown, Rama S. Gadepalli, Sarah L. Miles, John M. Rimoldi, Gary O. Rankin, Monica A. Valentovic, Maria T. Tirona, Paul T. Finch, Joshua A. Hess, and Piyali Dasgupta. Nonpungent N-AVAM Capsaicin Analogues and Cancer Therapy. Journal of Medicinal Chemistry 2021 64 (3), 1346-1361. DOI: 10.1021/acs.jmedchem.0c01679
Comments
Copyright © 2021 American Chemical Society.